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Abstract
Teneurins are a family of highly conserved pair-rule proteins involved in morphogenesis and
development of the central nervous system. Their function in adult tissues and in disease is
largely unknown. Recent evidence suggests a role for dysregulated expression of Teneurins
in human tumors, but systematic investigations are missing. Here, we investigated Teneurin-2
and Teneurin-4 expression in various cancer cell lines and in ovarian tumor tissues. Teneurin-
2 and Teneurin-4 were expressed in most of the breast cancer cell lines tested. Teneurin-4
was also detected in ovarian cancer cell lines, and throughout ovarian tumors and normal
ovary tissue. Ovarian tumors with low Teneurin-4 expression showed less differentiated phe-
notypes and these patients had shorter mean overall survival. Similarly, Teneurin-2 expres-
sion correlated with overall survival as well, especially in patients with serous tumors. In the
various cell lines, 5-Aza-cytidine-induced changes in DNA methylation did not alter expression
of Teneurin-2 and Teneurin-4, despite the existence of predicted CpG islands in both genes.
Interestingly, however, we found evidence for the control of Teneurin-2 expression by the
oncogenic growth factor FGF8. Furthermore, we identified multiple transcript splicing variants
for Teneurin-2 and Teneurin-4, indicating complex gene expression patterns in malignant
cells. Finally, downregulation of Teneurin-4 expression using siRNA caused a cell-type
dependent increase in proliferation and resistance to cisplatin. Altogether, our data suggest
that low Teneurin-4 expression provides a growth advantage to cancer cells and marks an
undifferentiated state characterized by increased drug resistance and clinical aggressiveness.
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We conclude that Teneurin-2 and Teneurin-4 expression levels could be of prognostic value
in ovarian cancer.
Introduction
Teneurins (Ten-M/ODZ) are highly conserved pair-rule proteins with fundamental roles in
embryonic development [1–4], in particular as regulators of neuronal pathfinding within the
central nervous system [4–7]. Vertebrates possess four distinct teneurin genes (TENM 1–4),
which encode related and highly conserved type II transmembrane glycoproteins of *300
kDa [4]. Expression of teneurin genes is tightly regulated in space and time to yield non-
redundant patterns within the evolving nervous system and in regulatory sites of morphogene-
sis, such as the limb buds and developing eyes [8–10]. At the molecular level, Teneurins can
undergo dimerization mediated by covalent bridging between adjacent cysteine residues in
their extracellular domains [11]. This interaction is essential for homophilic binding during
targeted recognition and selective cell-cell adhesion between neighboring neurons [12,13], a
process that can guide neuronal connectivity and might drive neuronal regeneration. On the
other hand, the intracellular domain (ICD) of some Teneurins can be cleaved upon homophi-
lic interactions and translocate to the nucleus [14], where it could function in transcriptional
control [15]. Further evidence has suggested a tight interplay between Teneurins and cytoskel-
etal components. Teneurin-1 (herein termed Ten-1) can interact with CAP/Ponsin [15], an
adaptor protein involved in the regulation of actin polymerization [16]. As a result, Ten-1 ICD
translocates to the nucleus and colocalizes with the methylation-dependent repressor MBD1,
which is consistent with the postulated role of Teneurins in controlling gene expression. Addi-
tional data showed that disruption of the actin cytoskeleton can impair homophilic Teneurin
binding [13] and, conversely, interference with Teneurin-mediated intercellular contact can
impair microtubule and spectrin architecture during synaptogenesis [17]. Teneurins have also
been implicated in the maintenance of basal membrane integrity [18]. Current data thus point
to a functional interdependence of Teneurins and cytoskeletal components.
Impaired expression of Teneurins derived from germline alterations has been associated
with phenotypes consistent with their essential role during embryogenesis. Hence, mice lack-
ing Ten-3 showed localized visual impairments that limit binocular vision [19,20], and a simi-
lar phenotype was recently described for a Ten-2 knockout [21]. Concordantly, a homozygous
null mutation in human Ten-3 was identified in a family with microphthalmia and visual
defects [22]. Partial deletions affecting the TENM1 gene were further detected in a family with
an X-linked lymphoproliferative disorder [23], although a definite genotype-phenotype rela-
tion could not be unambiguously established. Current findings are thus consistent with delete-
rious effects of Teneurin deficiency on specific morphogenetic processes. In contrast, it is
currently not known which functions Teneurins may fulfill in adult tissues and if their expres-
sion remains essential at such stage. Likewise, a role for somatic changes has not been
explored.
Using in silico analysis of transcriptomics data, we recently found evidence for altered
expression of Ten-2 and Ten-4 in various tumor types [24], and expression of Ten-2 at the pro-
tein level has been detected in malignant pleural mesothelioma using a chemo-proteomic
strategy [25]. Moreover, recurrent structural changes in the TENM3 gene have been identified
in neuroblastoma, and low Ten-3 mRNA levels in these tumors were associated with shorter
patient survival [26]. The authors proposed that alterations in Teneurins and other genes
Teneurins and prognosis of ovarian cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0177244 May 4, 2017 2 / 24
http://www.conicyt.cl/fondap/. Both funding
sources depend from the "Comisio´n Nacional de
Investigacio´n Cientı´fica y Tecnolo´gica" (CONICYT),
from the Government of Chile (http://www.conicyt.
cl/).
Competing interests: The authors have declared
that no competing interests exist.
affecting neurite outgrowth could be associated with high-risk neuroblastoma. In spite of this
data, studies systematically investigating the function of Teneurins in tumor formation and
malignant progression are scarce and were all derived from incidental findings. Based on the
above evidence, here we examined the expression of Ten-2 and Ten-4 in tumor cell lines of
various histotypes and in ovarian tumor tissues and normal ovary tissue as control to delineate
for the first time potential mechanisms of Teneurin regulation in human tumors. Further-
more, we investigated the effect of targeted Teneurin downregulation using siRNA on tumor
cell proliferation and resistance to cisplatin.
Materials and methods
Patients and tumor samples
The use of human tissue samples was approved by the Ethics Committees of all participating
institutions involved in providing and/or analyzing the samples (Comite´ de E´tica de la Investi-
gacio´n, Faculty of Medicine, Clı´nica Alemana—Universidad del Desarrollo, http://medicina.
udd.cl/centro-bioetica/sobre-el-centro/comite-de-etica/; and Comite´ E´tico-Cientı´fico, Faculty
of Medicine, Pontificia Universidad Cato´lica de Chile http://facultadmedicina.uc.cl/comite/
comite.html). A total of 77 frozen samples (62 ovarian tumors, 10 benign lesions, and 5 normal
ovaries) were included in the study, and for immunohistochemical detection of Ten-2, one fro-
zen biopsy of a mammary tumor was used. All samples were obtained with written informed
consent from patients with exception of 12 archived biopsies corresponding to previously
deceased patients. To protect patient confidentiality, all samples were ciphered and handled
anonymously. Clinical diagnosis was based on standard histological examination of biopsies
by pathologists of the different participating centers.
Cell culture
Cell lines derived from breast (BT474, MCF7, MDA-MB231, T47D and ZR75), ovarian
(Ovca420, Ovcar3 and Skov3), cervical (HeLa) and gastric (MKN45 and SNU1) cancer, and
the neuroblastoma cell line SHSY5Y, were maintained in DMEM with 10% fetal bovine serum
(HyClone, Thermo Scientific, South Logan, UT), 2 mM L-glutamine, and 40 μg/ml gentami-
cin, in a humidified incubator at 37˚C with 5% CO2.
Analysis of gene expression
RNA purification and reverse transcription. Cell line RNA was purified with the Pure-
LinkTM RNA Mini Kit (Ambion, Carlsbad, CA) and concentrations were measured in a Nano-
Drop 2000 (Thermo Scientific, Wilmington, DE) spectrophotometer. RNA (500 ng) was
reverse-transcribed in 20 μl using high performance MMLV reverse transcriptase (Epicentre,
Madison, WI) according to instructions. For frozen tumors, 80–100 mg tissue in 1 ml chilled
Trizol (Ambion) were homogenized on a Precellys-24 tissue lyser (Bertin Technologies, Mon-
tigny, France) 3 times 30 sec at 6500 rpm using 2.8 mm zirconium oxide beads. RNA integrity
was evaluated by electrophoresis on 2% agarose gels. Reverse transcription of 400 ng RNA was
performed in 20 μl using the High-Capacity cDNA Reverse Transcription kit (Applied Biosys-
tems, Foster City, CA) as instructed. We previously optimized this system to warrant non-sat-
urated, linear cDNA synthesis and amplification by real-time PCR [25].
PCR and real-time PCR. Standard PCR reactions in 30 μl contained 1x Reaction Buffer
(Bioline, Taunton, MA), 1.5–2.5 mM MgCl2, 200 μM of each dATP, dCTP, dGTP and dTTP,
0.2 μM of each forward and reverse primers, 0.75 U MangoTaqTM (Bioline), and 1 μl cDNA.
Amplifications were performed in an Applied Biosystems 2720 thermal cycler. Quality of
Teneurins and prognosis of ovarian cancer
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cDNA was checked by amplification of β2-microglobulin. Primer sequences are summarized
in S1 Table. Selected PCR fragments were subcloned into the pGEM-T Easy vector (Promega,
Madison, WI), and sequenced for identity confirmation (Macrogen, Seoul, Korea). For real-
time PCR, predesigned TaqMan assays (Applied Biosystems) were used as instructed. Amplifi-
cations were performed in an Mx3005P thermocycler (Agilent Technologies, Santa Clara, CA)
in 12 μl containing 1 μl cDNA. Real-time PCR data was analyzed with the MxPro software
(Agilent) as described [27]. PCR reactions were performed in duplicates (cell lines) or tripli-
cates (tumor tissues), and included two normalizing assays (GAPDH and B2M). TaqMan
assays used were Hs99999907_m1 (B2M), Hs99999905_m1 (GAPDH), Hs00393060_m1
(TENM2), Hs01008081_m1 (TENM4), Hs00608023_m1 (BCL2), Hs004194392_s1 (BIRC5),
Hs00234387_m1 (CASP3), Hs01018151_m1 (CASP8), and Hs00900055_m1 (VEGFA).
Methylation analysis. Two applications were used for identification of CPG clusters in
Teneurin genes. The first consisted on sequence analysis with the EMBOSS-CPGPlot program
(http://www.ebi.ac.uk/Tools/seqstats/emboss_cpgplot/) using standard settings, the second
used the more stringent Takai-Jones parameters [28]. For DNA demethylation, cultured cells
were incubated for 72 h with 1μM 5-Azacytidine and gene expression was measured by
RT-PCR as indicated above.
Gene silencing by siRNA transfection. Cells were reverse-transfected in 24-well plates
using siPORT NeoFX (Applied Biosystems) transfection reagent as instructed. In brief, 1 μl
siPORT NeoFX and 2.5 μl Silencer Select siRNA (Ambion) were each diluted to 25 μl in Opti-
MEM I medium (Gibco, Grand Island, NY) and mixed to 50 μl final volume after 10 min. The
mixture was added to 40000 freshly trypsinized cells in 450 μl culture medium containing 2%
FCS. Cells were incubated for 24–72 h without replacing the medium. Biological duplicates
were performed for each treatment.
Immunohistochemistry
Cells grown on uncoated glass coverslips were fixed for 15 min in 3% paraformaldehyde.
Endogenous peroxidase activity was quenched for 20 min in 0.1% H2O2, and cells were per-
meabilized for 5 min in 0.05% saponin (Calbiochem, La Jolla, CA). Immunohistochemical
staining was performed using the Elite Universal Vectastain kit (Vector, Burlingame, CA) as
instructed. Incubation with primary antibodies was done overnight at 4˚C. Staining was visu-
alized by 1–3 min incubation with 3,3’-diaminobenzidine (Vector). Cells were counterstained
with hematoxylin and coverslips were mounted with Vectamount AQ (Vector). For one frozen
biopsy, sections were fixed with acetone and stained following the same procedure, but using
Vector Red (Vector) as chromogen. Staining was analyzed on an Olympus CX31 microscope
and images were recorded on a ProgRes C3 (Jenoptik, Jena, Germany) digital camera. Primary
antibodies were DOC4-T15 and DOC4-M17 (Santa Cruz Biotechnology, Dallas, TX) for Ten-
4, and HPA038420 (Sigma-Aldrich, St. Louis, MO) for Ten-2.
Cell viability and cytotoxicity determinations
Cells in 96-well plates were seeded at 3000 cells/well and allowed to attach for 24 h at 37˚C. For
cytotoxicity measurements, cisplatin (Sigma-Aldrich) was added and incubation was contin-
ued for 48–96 h. Cell viability was determined using the MTS-based CellTiter 961 AQueous
One Solution Cell Cytotoxicity Assay (Promega, Madison, WI) as instructed. Absorbance at
570 nm was read on a Phomo Autobio Microplate Reader (Autobio Labtec Instruments,
Zhengzou City, P.R. China). All measurements were performed in triplicates. For concomitant
treatment with siRNAs and cisplatin, siRNAs were added when plating cells as outlined above.
Teneurins and prognosis of ovarian cancer
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Statistics analysis
For real-time PCR and MTS, differences between mean values were analyzed by parametric
comparison of independent means using the EPIDAT 3.1 software, with CI95% and consider-
ing equal variances. Overall survival was analyzed by Kaplan-Meier estimates and log rank
tests using the SPSS version 21.0 (IBM SPSS Inc., Chicago, Illinois) software. Owing to the
small case size, the threshold to rank teneurin expression as “high” or “low” was assigned to
generate groups with comparable case numbers, which set the cut-off close to median teneurin
values. The differences between teneurin mean values according to tumor differentiation, and
mean survival in different patient subgroups, was analyzed by Student’s t-test with P<0.05
regarded as significant.
Results
Complex expression patterns of Ten-2 and Ten-4 in cancer cells
So far, expression of Teneurins in human tumors has been scarcely investigated. Using
RT-PCR to screen a series of cell lines derived from breast, ovarian and cervix cancer, and
from neuroblastoma, we could detect widespread expression of Ten-4 throughout most of
these tumor cells (Fig 1A). In contrast, Ten-2 mRNA was primarily expressed in breast and
cervix cancer and in neuroblastoma cells, and migrated as two discrete amplification bands
(Fig 1A). Gastric cancer cell lines appeared to express these Teneurins at low to undetectable
levels, which agrees with our previous observation based on search of the Human Protein
Atlas repository [24]. The identity of all PCR products was validated by subcloning and
sequencing, and confirmed that amplified sequences entirely matched those of predicted Ten-
2 and Ten-4 transcripts (Genbank accessions NM_001122679.1 and NM_001098816.2,
respectively).
Consistent with transcript data, Ten-2 and Ten-4 protein expression could be visualized by
immunohistochemistry in a breast tumor sample and in Ovcar3 ovarian cancer cells, respec-
tively (Fig 1B). Immunoreactivity was mainly localized to perinuclear and cytoplasmic areas,
and for Ten-4, sites of intercellular contact were also stained. This is concordant with valida-
tion results reported for the Ten-2 antibody used (The Human Protein Atlas, http://www.
proteinatlas.org/ENSG00000145934), while surface staining was expected from the predicted
subcellular localization of Teneurins and from previous immunostaining studies [29]. Cyto-
plasmic localization has also been reported for Ten-1 in papillary thyroid carcinoma [30].
Immunohistochemical anaylsis of additional cell lines is shown in S2 Fig and exhibited consis-
tent staining patterns.
By Western blotting, full-sized Ten-4 (*300 kDa) could be detected in SHSY5Y neuroblas-
toma cells, which had the highest Ten-4 transcript level among the cell lines tested (Fig 1C and
S1A Fig). A secondary band was detected at *120 kDa in most cell lines, which is compatible
with the band pattern specified by the manufacturer of this antibody and might correspond to
a cleaved or alternatively spliced subspecies. This is in line with the multiple splice variants
encountered during sequence-based verification of Teneurin amplification products. For Ten-
2, we could identify a conserved splicing variant inserting 27 bp between exons 12 and 13 (Fig
2) [31], additional splicing variants involving the third and fourth exons, and an alternative
translation initiation site within the second intron of the predicted TENM2 gene (S3 Fig). We
termed it exon 1’ since it was the first exon whose expression could clearly be confirmed in sev-
eral cell lines that lacked detectable expression from predicted exons 1 and 2 (as defined in
Genbank accession NM_001122679.1) (S1B Fig). Transcript variants were also identified for
TENM4 (summarized in S2 Table). Taken together, these data confirm that Ten-2 and Ten-4
Teneurins and prognosis of ovarian cancer
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are expressed in human tumor cells. Expression patterns appear complex, with frequent coex-
istence of alternatively spliced transcript forms and concomitant presence of both Teneurins
in some of the cell lines analyzed.
Since EMX2 is a transcription factor implicated in the control of Teneurin gene expression
[32,33], we searched for evidence of a potential association of EMX2 and the Teneurins in
tumor cells. As shown in Fig 1A, concomitant expression of Ten-4 and EMX2 was indeed
observed in SHSY5Y neuroblastoma and in ovarian cancer cells, whereas Ten-2 and EMX2
showed an inverse expression pattern in HeLa and in breast cancer cells. These data indicate
Fig 1. Expression of Teneurins in tumor cells. A, Expression of Ten-4 (TENM4), Ten-2 (TENM2) and EMX2
mRNA was analyzed in breast (BT474, MCF7, MDA-MB-231, T47D, ZR75), ovarian (Ovca420, Ovcar3, Skov3),
cervix (HeLa), neuroblastoma (SHSY5Y), and gastric (MKN45, SNU1) tumor cell lines by RT-PCR. Amplification
of Beta-2-microglobulin (B2-MG) was used as internal control. B, Immunohistochemical detection of Teneurins.
Ten-2 staining was visualized with Vector Red chromogen in breast cancer tissue (a, b) and Ten-4 with 3,3’-
diaminobenzidine (light brown staining) in Ovcar3 cells (c, d), at 40X (a, c, d) and 100X (b) magnification,
respectively. Nuclei were counterstained with hematoxylin. Staining was absent in the negative control (c) when
primary antibody was omitted. Arrow-heads mark punctuated peri-nuclear and cytoplasmic staining areas. The
arrow points to Ten-4 enrichment at intercellular contact sites. C, Western blot analysis of Ten-4 in cell line
extracts. The expected size of full-length Ten-4 is indicated by the arrowhead. A secondary band migrates at
*120 kDa. Migration of the molecular weight standards is indicated at the left.
https://doi.org/10.1371/journal.pone.0177244.g001
Teneurins and prognosis of ovarian cancer
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tissue-dependent expression patterns for EMX2 and the Teneurins in tumors. Although
EMX2 and Ten-4 were coexpressed in some cell lines, additional tissue-specific regulation
mechanisms must exist in tumors lacking EMX2 expression.
Prevalent expression of Ten-4 in benign and malignant ovarian tissues
The screening of cell lines revealed that Ten-4 was frequently expressed in breast and ovarian
cancer cells (Fig 1A). Based on these findings, we analyzed Ten-4 expression in frozen biopsies
of tumors, benign lesions and normal tissue derived from ovaries. The corresponding patient
data are summarized in S3 Table. As in ovarian cancer cell lines, we could detect Ten-4 and
concomitant expression of EMX2 mRNA in all tissue samples examined, independent of their
histology and malignant condition (Fig 3). However, differences existed in transcript levels, as
revealed by comparative assessment using real-time PCR (Fig 4A). For instance, mucinous
tumors showed lower and borderline lesions higher Ten-4 mRNA (means -1.76 vs. 1.90,
respectively; P < .001, t-test), a trend also detected for Ten-2 (means 1.20 vs. 3.79, respectively;
P = .012; S4A Fig). For the entire group of measurements, mean cτ values were significantly
higher for Ten-2 than for Ten-4 (means 29.04 vs. 23.49; P< .001). Although absolute
Fig 2. Identification of Ten-2 splice variant. A, Position of PCR primers (arrowheads), expected
amplification product (solid line), and 27 bp insert within the Ten-2 mRNA. Vertical lines denote predicted
splice sites and rhombs mark the position of extracellular EGF-repeats. B, Ten-2 RT-PCR amplification
products obtained in breast and ovarian cancer cells using primers outlined in A. The position of bands (400
and 427 bp) is marked at the right. C, Scheme showing site of alternative splicing, and sequence of 27 bp
insert with predicted amino-acids based on predicted, in-frame ORF.
https://doi.org/10.1371/journal.pone.0177244.g002
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quantification was not performed, this large difference suggests that Ten-2 transcript levels
were comparatively lower than those of Ten-4, a finding compatible with the PCR measure-
ments in cell lines (Fig 1A).
To assess if expression of Teneurins was associated with clinicopathological parameters, we
analyzed the larger subgroup of serous tumors. We found that Ten-4 mRNA levels were signif-
icantly higher in the group of well differentiated (Grades I + II) than in the group of less differ-
entiated (Grade III + undifferentiated) tumors (means 1.63 vs. -0.83, respectively; P< .001, t-
test) (Fig 4B). The same trend was observed for Ten-2. Although in this case the association
was not significant (means 2.76 vs. 1.32, respectively; P = .078) (S4B Fig), removal of a single
outlier value sufficed to achieve significance (P = .035), suggesting that association with tumor
differentiation might also hold true for Ten-2.
Since loss of differentiation is a hallmark of increased malignancy and aggressiveness of
cancer [34], we analyzed patient survival with regard to tumor differentiation and Teneurin
expression. As expected, the mean survival was longer for patients with better differentiated
(GI + GII) than with less differentiated (GIII + undifferentiated) serous tumors (51.6 vs. 24.2
months, respectively, P = .006, t-test), but the difference in overall survival was not significant
(P = 0.203, log rank test). In contrast, decreased expression of Ten-2 was significantly
Fig 3. Expression of Ten-4 and EMX2 mRNA in ovarian tissues. Ten-4 (TENM4) and EMX2 mRNA levels were analyzed by RT-PCR in
ovarian tumors, benign lesions, and normal ovaries. Patient sample codes are indicated on top of the figure and the corresponding tissue types
underneath. Beta-2-microglobulin (B2-MG) was used as internal amplification control. BLK, no-template negative control.
https://doi.org/10.1371/journal.pone.0177244.g003
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associated with shortened overall survival in patients with any malignant ovarian tumor (Fig
5A), (P = .025), and highly significantly in the subgroup with serous carcinomas (Fig 5B),
(P = .005). Mean survival was 50.0 vs. 23.8 months (low vs. high Ten-2, respectively, P = .008,
t-test) for patients with serous carcinomas, and 48.5 vs. 30.2 months (P = .026) for patients
with any malignant tumor. For Ten-4, decreased expression was associated with shorter mean
survival in patients with serous carcinomas (49.7 vs. 21.4 months, low vs. high Ten-4, respec-
tively; P = .004, t-test) or with any malignant tumor (47.5 vs. 29.5 months, P = .029). However,
overall survival did not significantly differ between both groups (P = .105 for serous tumors,
and P = .126 for any malignant tumor, log rank test), (S5 Fig). To obtain additional support for
the observed trends, we used the Kaplan-Meier Plotter tool (http://kmplot.com/analysis/) to
analyze overall survival of patients with serous ovarian carcinoma based on publicly accessible
microarray expression data for Ten-4 and Ten-2. As in our study, cut-offs were set at median
Teneurin values to generate comparable groups with high and low expression. Data from 1207
patients could be queried based on Ten-4 expression but only 523 patients had available data
for Ten-2. As shown in S6 Fig, lower Ten-4 expression was significantly associated with short-
ened overall survival (P = 0.027) in patients with serous ovarian carcinoma. Although the same
trend was observed for Ten-2, it did not attain statistical significance (P = 0.39). The latter was
Fig 4. Detection of Ten-4 mRNA in ovarian tissues by real-time RT-PCR. A, Ten-4 mRNA levels were analyzed in 77 ovarian
samples corresponding to serous carcinoma (SC, shaded bars), mucinous tumors (MC, dark), endometroid tumors (E, lined),
borderline tumors (Bo, white), benign lesions (Be, dashed), normal ovaries (N, grey), and stromal tumors (St, dotted bars). B,
Based on grading, tumors were assigned into the well differentiated (GI, shaded bars, plus GII, white bars) or poorly differentiated
(GIII, dashed bars, plus undifferentiated, dark bars) group, and plotted according to Ten-4 expression levels. Values were
normalized to Beta-2-microglobulin content. Ten-4 ratios are expressed as log2 of fold-change and error bars indicate standard
deviations for triplicate measurements. Fold-change was calculated using a benign lesion as calibrator.
https://doi.org/10.1371/journal.pone.0177244.g004
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based on pooled results from several smaller patient cohorts, which suggests that additional
data might be required for reliable analysis. Taken together, our data and the results obtained
in silico show concordant trends and agree with recent findings recently reported for other
cancers (see Discussion). In synthesis, we have shown a predominant expression of Ten-4 in
Fig 5. Kaplan-Meier survival curves according to Ten-2 expression levels. Survival was analyzed for
patients with any malignant ovarian tumor (A, n = 62) and for the subgroup with serous carcinomas (B, n = 40)
by Kaplan-Meier estimates and log rank tests. Curves correspond to patients with low (solid lines) and high
(dotted lines) Ten-2 expression levels. Owing to the small number of patients, the threshold to rank Ten-2
expression as high or low was assigned as to generate two groups of comparable size.
https://doi.org/10.1371/journal.pone.0177244.g005
Teneurins and prognosis of ovarian cancer
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human ovary and identify Ten-2 and Ten-4 as potential prognostic factors in ovarian cancer.
In ovarian tumors, Teneurin transcript levels tend to decrease as differentiation is lost.
Control of Teneurin gene expression in tumor cells
Effect of DNA demethylating treatment. Epigenetic changes are common in cancer and
can contribute to dysregulated expression of oncogenic and tumor suppressor genes [35]. We
thus sought for evidence of a methylation-mediated regulation of Teneurin gene expression.
In effect, increased methylation of TENM3 upstream sequences had previously been reported
in breast ductal carcinomas in situ [36], and sequence-based prediction of CpG clusters (see
Materials and Methods) identified CpG-rich islands surrounding the predicted ATG tran-
scription initiation site in the Ten-4 gene (S7 Fig). CpG clusters were also present in introns of
both Ten-2 and Ten-4 genomic regions. In spite of this, demethylating treatment of breast,
ovarian and gastric cancer cells with 5-Azacytidine (5AzaCy) failed to induce expression of
Ten-2 or Ten-4 in cells lacking basal expression of either gene (Fig 6). This was consistent with
results obtained by in silico analysis of transcriptomic data derived from Decitabine-treated
breast and ovarian cancer cell lines (S4 Table). Methylation-mediated control of Teneurin
expression might thus be constrained to the TENM3 gene or show tumor-dependent
differences.
Control of Ten-2 gene expression by FGF8. In cancer, FGF family members are involved
in induction of autocrine cell growth [37,38] and some could be of prognostic value [39–41].
Previous experiments with chicken embryos demonstrated that Ten-2 gene expression can be
induced by FGF8 [31]. We therefore tested the effect of exogenous FGF8 in Skov3 and Ovcar3
cells, which showed low endogenous expression of both FGF8 and Ten-2 (S8 Fig). As shown
in Fig 7A, FGF8 induced a dose-dependent increase in Ten-2 mRNA in Skov3 cells, but
showed an opposite effect in Ovcar3 cells, the latter achieving significance (P = .0131 and P =
.0132, for 5 and 50 ng/ml FGF8, respectively, parametric comparison of independent means).
FGF8 further induced a modest increase in proliferation in Skov3 cells (8% at 100 ng/ml
FGF8, P = .0125), but a stronger opposite effect in Ovcar3 (Fig 7B) (P = .0017 and P = .0137, at
10 and 20 ng/ml FGF8 respectively). At 10 ng/ml FGF8, the difference in proliferation between
both cell lines was highly significant (P = .0007). These cell lines do not harbor FGFR2 muta-
tions that could impair receptor activation [42], but only Skov3 cells express the FGFR2-IIIc
splicing variant involved in FGF8-mediated responsiveness [43,44] (S8 Fig). These data
strongly suggest that expression of Ten-2 is responsive to FGF8 in ovarian cancer cells, but
that effects are tumor-specific and might depend on particular FGFR isoforms and/or on other
downstream signaling molecules.
Effect of Teneurin down-regulation on cancer-relevant cell responses
The function of Teneurins in tumor cells is still completely unknown. We thus used RNA
interference to reduce the expression of Ten-2 and Ten-4 in various cancer cell lines, and ana-
lyzed the effects on cell proliferation and on the expression of representative genes involved in
apoptosis and angiogenesis. In different cell lines, siRNAs reduced Ten-2 and Ten-4 mRNA
levels by 80–85% and by 70–90%, respectively, which however did not cause consistent effects
on the expression of BCL2, BIRC5, CASP3, and CASP8 (S9 Fig). Similarly, VEGF mRNA levels
were not significantly altered, although a potential role of Ten-4 in angiogenesis was previously
suggested based on its immunolocalization in coronary and tumor blood vessels [45,46]. In
contrast, we consistently measured a *20% increase in proliferation at 72 h in MCF7 and
BT474 cells treated with Ten-4-specific siRNA, with the latter achieving significance (P =
.0024, parametric comparison of independent means) (Fig 8A). These results suggest a
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potential of Ten-4 to affect tumor cell proliferation in a cell type-specific manner. Owing to
the small magnitude of the effect, more stringent molecular tools for Teneurin depletion will
be required to better assess the role of Teneurins on proliferation.
Fig 6. Demethylating Treatment of Cell Lines. Breast and ovarian cancer cell lines were treated with 1μM
5-Azacytidine for 72 h. Expression of Ten-2 (TENM2) Ten-4 (TENM4), EMX2 and transketolase-like protein-1
(TKTL1) mRNA was measured by RT-PCR (A) and real-time RT-PCR (B), expression of Beta-2-microglobulin
(B2-MG) was used as internal amplification control and as normalizing assay, respectively. Real-time PCR
ratios are expressed as relative change calibrated against the highest value in each group. TKTL1 was used as
demethylation-responsive control gene. BLK, no-template negative control.
https://doi.org/10.1371/journal.pone.0177244.g006
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Previously, massive overexpression of Ten-2 was reported in a vincristine-resistant Skov3
breast cancer subline, although a causal relationship between Ten-2 levels and drug resistance
was not assessed [47]. Here, we found that downregulation of Ten-4 in Skov3 cells for 48 h
decreased the sensitivity to cisplatin (Fig 8B), with mean IC50 values of 8.83 μM and 12.01 μM
for untreated and siRNA-treated cells, respectively (P = .0012, parametric comparison of inde-
pendent means) (Fig 8C). The difference to vehicle- and scrambled-treated controls was also
significant (P = .0036 and P = .0191, respectively). Similarly, downregulation of Ten-2 also
Fig 7. Effect of FGF8 treatment on Ten-2 expression and on Proliferation. A, Relative Ten-2 mRNA
levels were measured by real-time RT-PCR in Skov3 and Ovcar3 ovarian tumor cells treated for 8 h with 0, 5
and 50 ng/ml FGF8b. Values were normalized to B2-MG content and ratios are expressed as relative change
calibrated against the untreated control. GAPDH is included as housekeeping control gene. B, Skov3 and
Ovcar3 cells were treated for 24 h with different doses of FGF8b, and cell viability was measured by MTS
assay.
https://doi.org/10.1371/journal.pone.0177244.g007
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Fig 8. Effect of Teneurin down-regulation on Cell proliferation and cisplatin sensitivity. A, Cells cultured in
96-well plates were treated for 72 h with 10 μM siRNAs or transfection vehicle, and cell growth was determined by
MTS assay. Values were normalized to vehicle-treated cells and are expressed as relative absorbance. All mea-
surements were performed in triplicates. Bars represent the mean of two biological replicates. Basal expression
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decreased the sensitivity to cisplatin (IC50 = 11.12) compared to untreated (P = .0027) and
vehicle-treated (P = .00135) cells, but not to scrambled siRNA treated cells (P = .175). Our data
demonstrate, at least for Ten-4, that its downregulation has potential to increase resistance to
anti-cancer drugs. Additional studies are warranted to explore the opposite condition of
Teneurin overexpression and how it impacts on drug sensitivity.
Discussion
The role of Teneurins in neuronal development has been vastly documented [48–50], but their
appearance in the field of oncology is recent and their phenotypic contribution to tumorigene-
sis and malignant progression is unclear. We previously identified Ten-2 as a potential bio-
marker for malignant mesothelioma [25], and found evidence for dysregulated expression of
Ten-2 and Ten-4 in other cancers through search of in the literature and by mining transcrip-
tomics datasets [24]. Here we report for the first time that Ten-2 and Ten-4 are expressed
throughout different tumor cell lines, and show that expression can be redundant and involve
the simultaneous presence of complex splicing forms. For Ten-2, some cell lines showed no
evidence for expression of predicted exons 1–2. Instead, transcriptional initiation occurred
from an alternative ORF upstream of exon 3. This would alter the N-terminal, intracellular
domain (ICD), potentially impairing phosphorylation-triggered signaling and conformational
changes, or the reported transcriptional activity of the cleaved ICD [14]. In contrast, all Ten-2
transcript variants retained a histidine- and proline-rich SH3 domain in exon 4, which should
preserve interaction with SH3-containing proteins such as the cytoskeletal adapter CAP/Pon-
sin [15]. This is relevant since interaction with cytoskeletal components seems crucial for
proper Teneurin function [48], and has been reported in various model systems [12,15,51].
Similarly, we identified an intron-coded insert in Ten-4 predicted to add a proline-rich
sequence to the ICD. This motif mediates recognition by proteins harboring SH3 or WW
domains, many of which have been implicated in cancer [52,53]. It should be emphasized that
an identical insertion was reported in murine Ten-4 isoforms (UniProt accessions Q3UHK6-2
and Q3UHK6-3, respectively). Such interspecies conservation was also confirmed by a Ten-2
splicing variant inserting 27 bp at the end of exon 12, which is highly homologous to a reported
avian isoform of unknown functional significance [31]. Altogether, these data suggest a func-
tional relevance of highly conserved Teneurin variants, which deserve further detailed charac-
terization in tumors and other tissues to better understand the biology of these proteins and
their impact in tumorigenesis.
As with their structural variability, the mechanisms controlling expression of Teneurins
have not been studied in detail, except for the transcriptional activation by FGF8-mediated sig-
naling and through the homeobox transcription factor EMX2 [31–33]. Here we found a strik-
ing and tissue-specific coexpression of EMX2 and Ten-4 in all ovary-derived tissues (n = 77)
and cell lines (n = 3) analyzed. This agrees with the essential role of EMX2 in gonadal develop-
ment [54], but among the Teneurins, only Ten-1 has been associated with organogenesis of
of Ten-4 was detected in all cells, and basal Ten-2 was detected in BT474 and Skov3, only. SiRNAs were
targeted against Ten-2 (TENM2), Ten-4 (TENM4), or scrambled sequences (CN1). B, Skov3 cells in 96-well
plates were treated for 48 h with 10 μM siRNAs and varying concentrations of cisplatin (CisPt), and the
fraction of live cells was determined by MTS assay. All measurements were performed in triplicates. SiRNAs
were directed against TENM2 (siTNM2), TENM4 (siTNM4), or a scrambled control sequence (siCN1);
Vehicle, medium with transfection solution; Medium, untreated control. C, IC50 values were calculated using
the GraphPad Prism® 6 (version 6.05) software, and mean values were plotted with the according standard
deviations. Significance was analyzed by parametric comparison of independent means using EpiDat.
https://doi.org/10.1371/journal.pone.0177244.g008
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the reproductive tract [18,55]. In fact, a concomitant increase of EMX2 and Ten-1 was recently
reported in the endometrium of infertile patients with Mu¨llerian duct anomalies, and the
authors suggested a role for EMX2-mediated upregulation of Ten1 in this pathology [56]. This
is highly reminiscent of the striking coexpression of Ten-4 and EMX2 observed in the ovary.
Further, since EMX2 knock-out mice showed Ten-4 downregulation in the brain [32], a func-
tional interaction between EMX2 and Ten-4 should be clarified in additional adult tissues,
including those of the reproductive tract. In tumor cells derived from other tissues, Teneurins
and EMX2 were not necessarily coexpressed. Our data thus support the existence of tissue-spe-
cific expression patterns and probably of distinct regulatory mechanisms. The same holds true
for FGF8, which showed cell line-specific effects on proliferation and on Ten-2 expression,
probably due to the presence of different FGFR2 isoforms or downstream signaling compo-
nents. Such findings are not unusual and have been reported for other FGF8-mediated regula-
tory processes [57]. Since FGF family members display oncogenic actions [58] that can drive
autocrine proliferation in cancers of the breast and ovary [37,59], the functional effects of
FGF8 on Ten-2 expression in these tumors could be relevant for tumorigenesis and tumor
growth, and therefore warrants further investigation. Finally, our data and in silico analyses do
not support a methylation-mediated control of Ten-2 and Ten-4 gene expression in tumor
cells, despite the presence of potential CpG-rich regions in both TENM2 and TENM4 genomic
sequences. Methylation of TENM3was reported in premalignant, non-invasive breast lesions,
but functional consequences were not addressed in that study [36]. With regard to regulatory
mechanisms, we thus conclude that EMX2 and FGF8 deserve an in-depth analysis in benign
and malignant ovarian tissues, which will require additional approaches beyond the aims of
this work. Further mechanisms controlling the expression of Teneurins under normal and
malignant conditions remain to be identified.
Due to their structural complexity and tissue-specific expression, functional analysis of
Teneurins in tumor cells will likely be less straightforward. In fact, our broad screen for effects
of Teneurin depletion on the expression of representative read-out genes implicated in angio-
genesis, cell survival or apoptosis, did not reveal significant changes in several cell lines tested.
However, we could identify a consistent increase in proliferation rates upon reduction of Ten-
4 in at least two cell lines (BT474 and Skov3). Moreover, the resistance of Skov3 cells to cis-
platin increased upon Ten-4 downregulation. This is the second report that associates changes
in Teneurin expression with an altered drug response in this cell line. Interestingly, Ten-2
transcript levels were increased >240-fold in vincristine-resistant Skov-3 cells. [47]. However,
it was not assessed whether Ten-2 overexpression was causative of vincristine resistance or sec-
ondary to other alterations in these cells. Vincristine is a microtubule-destabilizing agent act-
ing through a different mechanism than the DNA damaging drug cisplatin [60,61]. Teneurins
might thus intervene differently in a drug-dependent manner. Also, opposing effects might
compare to those of the adhesion molecule E-cadherin, whose expression decreases with tran-
sition to increased malignancy [62]. However, E-cadherin overexpression can occur as well
and involves shedding of proteolytically cleaved domains with oncogenic properties, a process
highly reminiscent of the C-terminal peptide (TCAP) spliced from Teneurins [63]. These
issues will require intense additional investigation. It should also be noted that reductions in
EMX2 have been associated with resistance to cisplatin in lung tumors [64] and have been pro-
posed as a predictive marker of drug resistance [65]. Although we did not measure absolute
EMX2 levels, it should be examined if reductions in EMX2 parallel those of Ten-4 in ovarian
tumors and underlie potential resistance mechanisms to this drug.
In line with the above findings, we show that decreased expression of Ten-4 was signifi-
cantly associated with loss of differentiation in serous ovarian carcinomas. This entirely agrees
with reported roles of Ten-4 in the regulation of differentiation, both as a positive [66] and a
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negative modulator [67]. Our data implies that reduced expression of Ten-4 might relate to
tumor dedifferentiation and increased proliferation, processes known to contribute to tumor
growth, malignant progression and disease aggressiveness [34].
With regard to a prognostic relevance, we found that ovarian cancer patients with
reduced tumor levels of Ten-2 had significantly shortened overall survival, and the trend
was close to significant for those with low Ten-4. This entirely matches findings reported
for neuroblastoma patients, where reduced Ten-3 expression in tumors was also associated
with poor survival [26]. Further, two recent articles reported a prognostic impact of Ten-1
overexpression in papillary thyroid carcinoma and prolactin pituitary tumors, respectively
[30,68]. In the former, Ten-1 overexpression was significantly associated with clinical indi-
cators including an advanced stage and extrathyroidal invasion, and was thus proposed as a
potential marker of disease progression. Accordingly, in pituitary tumors Ten-1 was upre-
gulated in aggressive-invasive samples. Together, current evidence thus strongly supports
the prognostic impact of Teneurin expression on patient survival, but it is evident that tis-
sue-specific differences exist and that both under- and upregulated Teneurin expression
can be of significance.
Considering the emerging association of Teneurins with malignancy, the question arises of
potential somatic changes targeting the TENM genes. Up or downregulated Teneurin expres-
sion could be an indirect consequence of changes in other cancer-related genes, such as altered
expression of EMX2 in some tumor types [64,69]. However, structural aberrations in the
TENM3, TENM4 and TENM2 genes were identified in neuroblastoma [26,70], and in the case
of Ten-4, expression of gene chimeras was demonstrated by RNA-Seq, strongly supporting a
functional involvement of these aberrations in tumor development [70]. Such translocations
were also reported in other tumors and tumor cell lines, although functional analyses were not
performed [70–73]. Further, nonsynonimous Ten-4 mutations have recently been identified
by WES in almost 50% of primary lymphomas of the central nervous system [74]. The fact that
single nucleotide variants can impact on Teneurin function is supported by the association of
germline changes with inheritable conditions. These include a null mutation of TENM3 in
microphtalmia [22] and missense mutations of TENM4 in essential tremor [75]. Importantly,
the latter study demonstrated that mutant Ten-4 species altered their localization pattern in
the cell membrane upon transfection, and affected axonal guiding in a zebra fish model. This
is a definite proof that pathogenic variants in Teneurin genes can be encountered in clinical
conditions, and that somatic variants in tumors are likely to be identified in the near future.
Further studies are mandatory to address all these upcoming issues.
Conclusions
In conclusion, our work is the first to purposely address Teneurin expression, regulation and
biological functions in human cancer. We identified tissue-specific expression of Ten-2 and
Ten-4 in tumor cell lines, and show complex and redundant expression of different Teneurin
splicing variants. The widespread expression of Ten-4 in normal and malignant ovarian tissues
deserves further investigation. The same holds true for the pending identification of mecha-
nisms regulating Teneurin expression in tumors and other adult tissues. Importantly, evidence
is accumulating of dysregulated Teneurin expression in several tumor types. Together with
their reported prognostic impact, a functional contribution to tumorigenesis and malignant
progression can be expected and should be studied further. Here we show that Teneurins are
associated with patient survival in ovarian cancer, possibly due to a regulatory effect on tumor
differentiation, cell proliferation and drug resistance.
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Supporting information
S1 Fig. Additional RT-PCR data of Ten-1 and Ten-2 Transcripts. A, Expression of Ten-2
(TENM2) and Ten-4 (TENM4) mRNA was measured by RT-PCR in cell lines indicated at the
bottom. Data are normalized to Beta-2-microglobulin and ratios are expressed as relative
change using Skov3 as calibrator. B, PCR analysis of expression of Ten-2 (TENM2) predicted
exons 1 and 2, and alternative exon 1’ in Skov3 and ZR75 cells. PCR was performed with inter-
nal primers for each exon. A human genomic DNA sample was used as positive amplification
control (+CTRL) and amplification of Beta-2-microglobulin (B2-MG) was used to control for
template quality.
(PDF)
S2 Fig. Immunohistochemical analysis of additional cell lines. MCF-7 (A, B), SKOV3 (C,
D), MDA-MB231 (E, F) and T47D (G, H) cells were subjected to immunohistochemical analy-
sis for Ten-2 (F, H) and Ten-4 (B, D), respectively. Staining was visualized with 3,3’-diamino-
benzidine and nuclei were counterstained with hematoxylin. All images were taken at 40X
magnification. Staining was absent in the negative controls (A, C, E, G) when primary antibod-
ies were omitted.
(PDF)
S3 Fig. Ten-2 mRNA splice variants detected in Skov3 ovarian cancer cells. A, multiple
Ten-2 amplification products obtained by RT-PCR between alternative exon 1’ (GeneBank
accession AK056053.1) and exon 4. The expected product size was 560 bp based on predicted
splicing sites (GeneBank accession NM_001122679) and assuming expression of all encom-
passed exons, or 350 bp for a transcript lacking exon 3. B, Transcript variants identified by
direct sequencing of PCR products depicted in Fig 1A. The corresponding transcripts and
PCR products are labelled A-D in both figures. Primer sequences are summarized in S1 Table,
transcript GeneBank accession numbers in S2 Table. Blk, no template control.
(PDF)
S4 Fig. Detection of Ten-2 mRNA in ovarian tissues by real-time RT-PCR. A, Ten-2 mRNA
levels were analyzed in 77 ovarian samples corresponding to serous carcinoma (SC, shaded
bars), mucinous tumors (MC, dark), endometroid tumors (E, lined), borderline tumors (Bo,
white), benign lesions (Be, dashed), normal ovaries (N, grey), and stromal tumors (St, dotted
bars). B, Based on grading, tumors were assigned into the well differentiated (GI, shaded bars,
plus GII, white bars) or poorly differentiated (GIII, dashed bars, plus undifferentiated, dark
bars) group, and plotted according to Ten-2 expression levels. Values were normalized to
Beta-2-microglobulin content. Ten-2 ratios are expressed as log2 of fold-change and error bars
indicate standard deviations for triplicate measurements. Fold-change was calculated using a
benign lesion as calibrator.
(PDF)
S5 Fig. Kaplan-Meier survival curves based on Ten-4 mRNA levels in tumors. Overall sur-
vival (OS) was analyzed for patients with serous ovarian carcinoma (A, n = 40) or with any
malignant ovarian tumor (B, n = 62) by Kaplan-Meier estimates and log rank tests. Curves cor-
respond to patients with low (solid lines) and high (dotted lines) Ten-4 expression levels.
(PDF)
S6 Fig. Kaplan-Meier survival curves based on analysis of expression arrays. Overall sur-
vival for patients with serous ovarian carcinoma was analyzed using publicly accessible data
for Ten-4 (A) and Ten-2 (B) expression with the Kaplan-Meier Plotter tool (http://kmplot.
com/analysis/). Affymetrix expression data were based on available single probes 213273_at
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and 231867_at for Ten-4 and Ten-2, respectively. Cut-offs were set at median values to gener-
ate comparable groups with high and low Teneurin expression. For Ten-4, the complete
patient set (n = 1207) could be queried. In contrast, TCGA data could not be evaluated for
Ten-2 since the corresponding probe was not included in these data sets. Accordingly, data
from 523 patients was used for Ten-2-based analysis. Numbers at the bottom of each figure
represent patients alive at the corresponding measurement time.
(PDF)
S7 Fig. Distribution of CpG island clusters in human Ten-2 and Ten-4 genomic DNA and
predicted transcripts. Figures represent human Ten-2 genomic DNA (A) and predicted
mRNA (B), and Ten-4 genomic DNA (C) and predicted mRNA (D), respectively. Prediction
was done using the EMBOSS-CPGPlot application (http://www.ebi.ac.uk/Tools/seqstats/
emboss_cpgplot/) with default parameters (length >200 bp; o/e ratio >0.6; C+G>50%; corre-
sponding CpG clusters are indicated by black arrowheads and shaded boxes), and also apply-
ing the more stringent criteria of Takai-Jones (length>500 bp; o/e ratio >0.65; C+G >55%;
clusters indicated by white arrows and dashed boxes). Blue bars represent predicted exons.
The location of alternative exon 1’ is marked by an asterisk. Blue arrowheads indicate tran-
scriptional start (ATG) and end (TAA, TGA) sites, respectively.
(PDF)
S8 Fig. RT-PCR analysis of FGF8-mediated signaling components. Shown are specific
amplification products for Ten-2 (TENM2), FGF8 and FGF receptors (FGF-R) 1 to 4 in breast
(BT474, MCF7, MDA-MB231, T47D, ZR75) and ovarian (Ovcar3, Skov3) cancer cell lines.
Beta-2-microglobulin (B2-MG) was used as internal amplification control. PCR fragment size is
indicated at the right. For FGF-R2, two isofoms were detected, showing the presence of a
known splicing variant (amplified at 406 bp) in Ovcar3, MCF7 and T47D cells. Endogenous
expression of FGF8 was prevalent in breast cancer cell lines. BLK, no-template negative control.
(PDF)
S9 Fig. Effect of Teneurin targeted siRNA treatment on the expression of selected genes.
Shown are representative results obtained with T47D breast cancer cells. Cultured cells in
24-well plates were treated for 72 h with transfection vehicle (V), or with 10 μM siRNAs
directed at Ten-2 (TN2), Ten-4 (TN4), or scrambled sequences (CN1, CN2). Gene expression
was measured by real-time RT-PCR. Values were normalized to expression of beta-2-micro-
globulin and are expressed as fold-change using vehicle-treated cells as calibrator. Ratios are
expressed as relative change calibrated against the vehicle-treated control. All measurements
were performed in duplicates. Bars represent the mean of two biological replicates. The genes
measured are indicated on top of each graph. The higher variability of Bcl2 mRNA measure-
ments is the result of very low basal expression in these cells. Comparable results were obtained
with other cell lines (not shown).
(PDF)
S1 Table. Summary of PCR primers used in this study. Primer sequences are listed in 5’-3’
direction. Locations refer to exon numbers. The expected size of all amplification products was
confirmed experimentally and by predictive in silico PCR (UCSC In-Silico PCR, http://genome.
ucsc.edu/cgi-bin/hgPcr?org=Human). () Exon 1’ corresponds to an alternative first exon iden-
tified in human Ten-2 transcripts in our work (see S1 Fig). A corresponding isolated cDNA
clone had previously been reported (GeneBank accession AK056053.1) which has not been inte-
grated into the predicted Ten-2 mRNA sequence (GeneBank accession NM_001122679).
(DOC)
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S2 Table. GenBank accession numbers for Ten-4 and Ten-2 transcript variants identified
in the Skov3 cancer cell line.
(DOCX)
S3 Table. Summary of patient data.
(DOCX)
S4 Table. In silico analysis of Ten-2 and Ten-4 gene expression in breast and ovarian cell
lines treated with the demethylating agent 5-aza-2’-deoxycytidine (Decitabine). Analysis of
two large-scale profiling data sets (N. Matsumara et al. Genome Res. 2011, 21:74–82; and D.S.
Shames et al. PLOS Medicine 2006, 3: e486). No significant changes (1.5-fold) were observed
in transcript levels for Ten-2 (ODZ2) and Ten-4 (ODZ4) upon treatment of breast and ovarian
cancer cell lines with 5-aza-2’-deoxycytidine (5-Aza-Cy). Gene probes are named according to
previous gene designation, before introduction of TENM consensus nomenclature.
(DOCX)
Acknowledgments
We are grateful to Soledad Lantadilla and Tamara Sa´nchez for technical assistance with isola-
tion of tumor RNAs and immunohistochemistry, and to Gabriela Repetto for support with the
supervision of participating students. Some of the cell lines used were kindly provided by Rolf
Stahel (Switzerland), and by Paulette Conget and Marco T. Nu´ñez (Chile).
Author Contributions
Conceptualization: AZ JAB IR.
Data curation: GADC CL.
Formal analysis: ID UZ-W AHC.
Funding acquisition: AZ AHC.
Investigation: RG GADC JEO CL MAV AZ PC.
Methodology: RG GADC JEO CL MAV AZ.
Project administration: AZ.
Resources: AZ IR JAB GO.
Supervision: AZ.
Validation: AZ RG GADC JEO CL MAV.
Visualization: AZ.
Writing – original draft: AZ.
Writing – review & editing: AZ AHC GO UZ-W RG.
References
1. Baumgartner S, Martin D, Hagios C, Chiquet-Ehrismann R. Tenm, a Drosophila gene related to tenas-
cin, is a new pair-rule gene. EMBO J. 1994; 13: 3728–3740. PMID: 8070401
2. Levine A, Bashan-Ahrend A, Budai-Hadrian O, Gartenberg D, Menasherow S, Wides R. Odd Oz: a
novel Drosophila pair rule gene. Cell. 1994; 77: 587–598. PMID: 7514504
Teneurins and prognosis of ovarian cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0177244 May 4, 2017 20 / 24
3. Baumgartner S, Chiquet-Ehrismann R. Tena, a Drosophila gene related to tenascin, shows selective
transcript localization. Mech Dev. 1993; 40: 165–176. PMID: 7684246
4. Tucker RP, Kenzelmann D, Trzebiatowska A, Chiquet-Ehrismann R. Teneurins: transmembrane pro-
teins with fundamental roles in development. Int J Biochem Cell Biol. 2007; 39: 292–297. https://doi.org/
10.1016/j.biocel.2006.09.012 PMID: 17095284
5. Young TR, Leamey CA. Teneurins: important regulators of neural circuitry. Int J Biochem Cell Biol.
2009; 41: 990–993. https://doi.org/10.1016/j.biocel.2008.06.014 PMID: 18723111
6. Kenzelmann D, Chiquet-Ehrismann R, Tucker RP. Teneurins, a transmembrane protein family involved
in cell communication during neuronal development. Cell Mol Life Sci. 2007; 64: 1452–1456. https://doi.
org/10.1007/s00018-007-7108-9 PMID: 17502993
7. Hong W, Mosca TJ, Luo L. Teneurins instruct synaptic partner matching in an olfactory map. Nature.
2012; 484: 201–207. https://doi.org/10.1038/nature10926 PMID: 22425994
8. Ben-Zur T, Feige E, Motro B, Wides R. The mammalian Odz gene family: homologs of a Drosophila
pair-rule gene with expression implying distinct yet overlapping developmental roles. Dev Biol. 2000;
217: 107–120. https://doi.org/10.1006/dbio.1999.9532 PMID: 10625539
9. Zhou X-H, Brandau O, Feng K, Oohashi T, Ninomiya Y, Rauch U, et al. The murine Ten-m/Odz genes
show distinct but overlapping expression patterns during development and in adult brain. Gene Expr
Patterns. 2003; 3: 397–405. PMID: 12915301
10. Kinel-Tahan Y, Weiss H, Dgany O, Levine A, Wides R. Drosophila odz gene is required for multiple cell
types in the compound retina. Dev Dyn. 2007; 236: 2541–2554. https://doi.org/10.1002/dvdy.21284
PMID: 17685476
11. Feng K, Zhou X-H, Oohashi T, Mo¨rgelin M, Lustig A, Hirakawa S, et al. All four members of the Ten-m/
Odz family of transmembrane proteins form dimers. J Biol Chem. 2002; 277: 26128–26135. https://doi.
org/10.1074/jbc.M203722200 PMID: 12000766
12. Rubin BP, Tucker RP, Brown-Luedi M, Martin D, Chiquet-Ehrismann R. Teneurin 2 is expressed by the
neurons of the thalamofugal visual system in situ and promotes homophilic cell-cell adhesion in vitro.
Development. 2002; 129: 4697–4705. PMID: 12361962
13. Beckmann J, Schubert R, Chiquet-Ehrismann R, Mu¨ller DJ. Deciphering teneurin domains that facilitate
cellular recognition, cell-cell adhesion, and neurite outgrowth using atomic force microscopy-based sin-
gle-cell force spectroscopy. Nano Lett. 2013; 13: 2937–2946. https://doi.org/10.1021/nl4013248 PMID:
23688238
14. Bagutti C, Forro G, Ferralli J, Rubin B, Chiquet-Ehrismann R. The intracellular domain of teneurin-2 has
a nuclear function and represses zic-1-mediated transcription. J Cell Sci. 2003; 116: 2957–2966.
https://doi.org/10.1242/jcs.00603 PMID: 12783990
15. Nunes SM, Ferralli J, Choi K, Brown-Luedi M, Minet AD, Chiquet-Ehrismann R. The intracellular domain
of teneurin-1 interacts with MBD1 and CAP/ponsin resulting in subcellular codistribution and transloca-
tion to the nuclear matrix. Exp Cell Res. 2005; 305: 122–132. https://doi.org/10.1016/j.yexcr.2004.12.
020 PMID: 15777793
16. Zhang H, Ghai P, Wu H, Wang C, Field J, Zhou G-L. Mammalian adenylyl cyclase-associated protein 1
(CAP1) regulates cofilin function, the actin cytoskeleton, and cell adhesion. J Biol Chem. 2013; 288:
20966–20977. https://doi.org/10.1074/jbc.M113.484535 PMID: 23737525
17. Mosca TJ, Hong W, Dani VS, Favaloro V, Luo L. Trans-synaptic Teneurin signalling in neuromuscular
synapse organization and target choice. Nature. 2012; 484: 237–241. https://doi.org/10.1038/
nature10923 PMID: 22426000
18. Trzebiatowska A, Topf U, Sauder U, Drabikowski K, Chiquet-Ehrismann R. Caenorhabditis elegans
teneurin, ten-1, is required for gonadal and pharyngeal basement membrane integrity and acts redun-
dantly with integrin ina-1 and dystroglycan dgn-1. Mol Biol Cell. 2008; 19: 3898–3908. https://doi.org/
10.1091/mbc.E08-01-0028 PMID: 18632986
19. Leamey CA, Merlin S, Lattouf P, Sawatari A, Zhou X, Demel N, et al. Ten_m3 regulates eye-specific
patterning in the mammalian visual pathway and is required for binocular vision. PLoS Biol. 2007; 5:
e241. https://doi.org/10.1371/journal.pbio.0050241 PMID: 17803360
20. Dharmaratne N, Glendining KA, Young TR, Tran H, Sawatari A, Leamey CA. Ten-m3 is required for the
development of topography in the ipsilateral retinocollicular pathway. PLoS ONE. 2012; 7: e43083.
https://doi.org/10.1371/journal.pone.0043083 PMID: 23028443
21. Young TR, Bourke M, Zhou X, Oohashi T, Sawatari A, Fa¨ssler R, et al. Ten-m2 Is Required for the Gen-
eration of Binocular Visual Circuits. J Neurosci. 2013; 33: 12490–12509. https://doi.org/10.1523/
JNEUROSCI.4708-12.2013 PMID: 23884953
Teneurins and prognosis of ovarian cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0177244 May 4, 2017 21 / 24
22. Aldahmesh MA, Mohammed JY, Al-Hazzaa S, Alkuraya FS. Homozygous null mutation in ODZ3
causes microphthalmia in humans. Genet Med. 2012; 14: 900–904. https://doi.org/10.1038/gim.2012.
71 PMID: 22766609
23. Mejstrı´kova´ E, Janda A, Hrusa´k O, Buckova´ H, Vlckova´ M, Hanca´rova´ M, et al. Skin lesions in a boy
with X-linked lymphoproliferative disorder: comparison of 5 SH2D1A deletion cases. Pediatrics. 2012;
129: e523–528. https://doi.org/10.1542/peds.2011-0870 PMID: 22271700
24. Ziegler A, Corvala´n A, Roa I, Brañes JA, Wollscheid B. Teneurin protein family: an emerging role in
human tumorigenesis and drug resistance. Cancer Lett. 2012; 326: 1–7. https://doi.org/10.1016/j.
canlet.2012.07.021 PMID: 22841666
25. Ziegler A, Cerciello F, Bigosch C, Bausch-Fluck D, Felley-Bosco E, Ossola R, et al. Proteomic surfa-
ceome analysis of mesothelioma. Lung Cancer. 2012; 75: 189–196. https://doi.org/10.1016/j.lungcan.
2011.07.009 PMID: 21835491
26. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, et al. Sequencing of
neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature. 2012; 483: 589–
593. https://doi.org/10.1038/nature10910 PMID: 22367537
27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR
and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25: 402–408. https://doi.org/10.1006/meth.2001.
1262 PMID: 11846609
28. Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc
Natl Acad Sci USA. 2002; 99: 3740–3745. https://doi.org/10.1073/pnas.052410099 PMID: 11891299
29. Kenzelmann D, Chiquet-Ehrismann R, Leachman NT, Tucker RP. Teneurin-1 is expressed in intercon-
nected regions of the developing brain and is processed in vivo. BMC Dev Biol. 2008; 8: 30. https://doi.
org/10.1186/1471-213X-8-30 PMID: 18366734
30. Cheng S-P, Chen M-J, Chien M-N, Lin C-H, Lee J-J, Liu C-L. Overexpression of teneurin transmem-
brane protein 1 is a potential marker of disease progression in papillary thyroid carcinoma. Clin Exp
Med. 2016
31. Tucker RP, Chiquet-Ehrismann R, Chevron MP, Martin D, Hall RJ, Rubin BP. Teneurin-2 is expressed
in tissues that regulate limb and somite pattern formation and is induced in vitro and in situ by FGF8.
Dev Dyn. 2001; 220: 27–39. https://doi.org/10.1002/1097-0177(2000)9999:9999<::AID-DVDY1084>3.
0.CO;2-B PMID: 11146505
32. Li H, Bishop KM, O’Leary DDM. Potential target genes of EMX2 include Odz/Ten-M and other gene
families with implications for cortical patterning. Mol Cell Neurosci. 2006; 33: 136–149. https://doi.org/
10.1016/j.mcn.2006.06.012 PMID: 16919471
33. Beckmann J, Vitobello A, Ferralli J, Brozˇ DK, Rijli FM, Chiquet-Ehrismann R. Human teneurin-1 is a
direct target of the homeobox transcription factor EMX2 at a novel alternate promoter. BMC Dev Biol.
2011; 11: 35. https://doi.org/10.1186/1471-213X-11-35 PMID: 21651764
34. Vang R, Shih I-M, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis,
clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009; 16:
267–282. https://doi.org/10.1097/PAP.0b013e3181b4fffa PMID: 19700937
35. Baylin SB, Jones PA. A decade of exploring the cancer epigenome—biological and translational impli-
cations. Nat Rev Cancer. 2011; 11: 726–734. https://doi.org/10.1038/nrc3130 PMID: 21941284
36. Tommasi S, Karm DL, Wu X, Yen Y, Pfeifer GP. Methylation of homeobox genes is a frequent and early
epigenetic event in breast cancer. Breast Cancer Res. 2009; 11: R14. https://doi.org/10.1186/bcr2233
PMID: 19250546
37. Valve E, Martikainen P, Seppa¨nen J, Oksjoki S, Hinkka S, Anttila L, et al. Expression of fibroblast
growth factor (FGF)-8 isoforms and FGF receptors in human ovarian tumors. Int J Cancer. 2000; 88:
718–725. PMID: 11072239
38. Mattila MM, Ha¨rko¨nen PL. Role of fibroblast growth factor 8 in growth and progression of hormonal can-
cer. Cytokine Growth Factor Rev. 2007; 18: 257–266. https://doi.org/10.1016/j.cytogfr.2007.04.010
PMID: 17512240
39. Birrer MJ, Johnson ME, Hao K, Wong K-K, Park D-C, Bell A, et al. Whole genome oligonucleotide-
based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prog-
nostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol. 2007; 25: 2281–
2287. https://doi.org/10.1200/JCO.2006.09.0795 PMID: 17538174
40. Wei W, Mok SC, Oliva E, Kim S, Mohapatra G, Birrer MJ. FGF18 as a prognostic and therapeutic bio-
marker in ovarian cancer. J Clin Invest. 2013; 123: 4435–4448. https://doi.org/10.1172/JCI70625
PMID: 24018557
Teneurins and prognosis of ovarian cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0177244 May 4, 2017 22 / 24
41. Chang J, Liu X, Wang S, Zhang Z, Wu Z, Zhang X, et al. Prognostic value of FGFR gene amplification
in patients with different types of cancer: a systematic review and meta-analysis. PLoS ONE. 2014; 9:
e105524. https://doi.org/10.1371/journal.pone.0105524 PMID: 25171497
42. Byron SA, Gartside MG, Wellens CL, Goodfellow PJ, Birrer MJ, Campbell IG, et al. FGFR2 mutations
are rare across histologic subtypes of ovarian cancer. Gynecol Oncol. 2010; 117: 125–129. https://doi.
org/10.1016/j.ygyno.2009.12.002 PMID: 20106510
43. Cole C, Lau S, Backen A, Clamp A, Rushton G, Dive C, et al. Inhibition of FGFR2 and FGFR1 increases
cisplatin sensitivity in ovarian cancer. Cancer Biol Ther. 2010; 10: 495–504. https://doi.org/10.4161/cbt.
10.5.12585 PMID: 20595807
44. Chandler LA, Sosnowski BA, Greenlees L, Aukerman SL, Baird A, Pierce GF. Prevalent expression of
fibroblast growth factor (FGF) receptors and FGF2 in human tumor cell lines. Int J Cancer. 1999; 81:
451–458. PMID: 10209961
45. Kenzelmann-Broz D, Tucker RP, Leachman NT, Chiquet-Ehrismann R. The expression of teneurin-4 in
the avian embryo: potential roles in patterning of the limb and nervous system. Int J Dev Biol. 2010; 54:
1509–1516. https://doi.org/10.1387/ijdb.103139dk PMID: 21136382
46. Kenzelmann-Broz D. Teneurins in development and disease [Internet]. University of Basel, Faculty of
Science, Basel, Switzerland; 2008. Available: http://edoc.unibas.ch/diss/DissB_8563
47. Buys TPH, Chari R, Lee EHL, Zhang M, MacAulay C, Lam S, et al. Genetic changes in the evolution of
multidrug resistance for cultured human ovarian cancer cells. Genes Chromosomes Cancer. 2007; 46:
1069–1079. https://doi.org/10.1002/gcc.20492 PMID: 17726699
48. Suzuki N, Numakawa T, Chou J, de Vega S, Mizuniwa C, Sekimoto K, et al. Teneurin-4 promotes cellu-
lar protrusion formation and neurite outgrowth through focal adhesion kinase signaling. FASEB J. 2014;
28: 1386–1397. https://doi.org/10.1096/fj.13-241034 PMID: 24344332
49. Antinucci P, Nikolaou N, Meyer MP, Hindges R. Teneurin-3 specifies morphological and functional con-
nectivity of retinal ganglion cells in the vertebrate visual system. Cell Rep. 2013; 5: 582–592. https://doi.
org/10.1016/j.celrep.2013.09.045 PMID: 24183672
50. Tran H, Sawatari A, Leamey CA. The glycoprotein Ten-m3 mediates topography and patterning of tha-
lamostriatal projections from the parafascicular nucleus in mice. Eur J Neurosci. 2015; 41: 55–68.
https://doi.org/10.1111/ejn.12767 PMID: 25406022
51. Zheng L, Michelson Y, Freger V, Avraham Z, Venken KJT, Bellen HJ, et al. Drosophila Ten-m and fila-
min affect motor neuron growth cone guidance. PLoS ONE. 2011; 6: e22956. https://doi.org/10.1371/
journal.pone.0022956 PMID: 21857973
52. Macias MJ, Wiesner S, Sudol M. WW and SH3 domains, two different scaffolds to recognize proline-
rich ligands. FEBS Lett. 2002; 513: 30–37. PMID: 11911877
53. Salah Z, Alian A, Aqeilan RI. WW domain-containing proteins: retrospectives and the future. Front
Biosci (Landmark Ed). 2012; 17: 331–348.
54. Miyamoto N, Yoshida M, Kuratani S, Matsuo I, Aizawa S. Defects of urogenital development in mice
lacking Emx2. Development. 1997; 124: 1653–1664. PMID: 9165114
55. Drabikowski K, Trzebiatowska A, Chiquet-Ehrismann R. ten-1, an essential gene for germ cell develop-
ment, epidermal morphogenesis, gonad migration, and neuronal pathfinding in Caenorhabditis elegans.
Dev Biol. 2005; 282: 27–38. https://doi.org/10.1016/j.ydbio.2005.02.017 PMID: 15936327
56. Zhu Y, Luo M, Huang H, Du X, Chen D, Xing Q, et al. HOXA10, EMX2 and TENM1 expression in the
mid-secretory endometrium of infertile women with a Mu¨llerian duct anomaly. Reprod Biomed Online.
2016; 32: 388–393. https://doi.org/10.1016/j.rbmo.2016.01.005 PMID: 26896429
57. Mott NN, Chung WCJ, Tsai P-S, Pak TR. Differential fibroblast growth factor 8 (FGF8)-mediated autore-
gulation of its cognate receptors, Fgfr1 and Fgfr3, in neuronal cell lines. PLoS ONE. 2010; 5: e10143.
https://doi.org/10.1371/journal.pone.0010143 PMID: 20405041
58. Chaffer CL, Dopheide B, Savagner P, Thompson EW, Williams ED. Aberrant fibroblast growth factor
receptor signaling in bladder and other cancers. Differentiation. 2007; 75: 831–842. https://doi.org/10.
1111/j.1432-0436.2007.00210.x PMID: 17697126
59. Marsh SK, Bansal GS, Zammit C, Barnard R, Coope R, Roberts-Clarke D, et al. Increased expression
of fibroblast growth factor 8 in human breast cancer. Oncogene. 1999; 18: 1053–1060. https://doi.org/
10.1038/sj.onc.1202392 PMID: 10023681
60. Stanton RA, Gernert KM, Nettles JH, Aneja R. Drugs that target dynamic microtubules: a new molecular
perspective. Med Res Rev. 2011; 31: 443–481. https://doi.org/10.1002/med.20242 PMID: 21381049
61. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharma-
col. 2014; 740: 364–378. https://doi.org/10.1016/j.ejphar.2014.07.025 PMID: 25058905
Teneurins and prognosis of ovarian cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0177244 May 4, 2017 23 / 24
62. David JM, Rajasekaran AK. Dishonorable discharge: the oncogenic roles of cleaved e-cadherin frag-
ments. Cancer Res. 2012; 72: 2917–2923. https://doi.org/10.1158/0008-5472.CAN-11-3498 PMID:
22659456
63. Chand D, Casatti CA, de Lannoy L, Song L, Kollara A, Barsyte-Lovejoy D, et al. C-terminal processing
of the teneurin proteins: independent actions of a teneurin C-terminal associated peptide in hippocam-
pal cells. Mol Cell Neurosci. 2013; 52: 38–50. https://doi.org/10.1016/j.mcn.2012.09.006 PMID:
23026563
64. Okamoto J, Hirata T, Chen Z, Zhou H-M, Mikami I, Li H, et al. EMX2 is epigenetically silenced and sup-
presses growth in human lung cancer. Oncogene. 2010; 29: 5969–5975. https://doi.org/10.1038/onc.
2010.330 PMID: 20697358
65. Yue D, Li H, Che J, Zhang Y, Tolani B, Mo M, et al. EMX2 Is a Predictive Marker for Adjuvant Chemo-
therapy in Lung Squamous Cell Carcinomas. PLoS ONE. 2015; 10: e0132134. https://doi.org/10.1371/
journal.pone.0132134 PMID: 26132438
66. Suzuki N, Fukushi M, Kosaki K, Doyle AD, de Vega S, Yoshizaki K, et al. Teneurin-4 is a novel regulator
of oligodendrocyte differentiation and myelination of small-diameter axons in the CNS. J Neurosci.
2012; 32: 11586–11599. https://doi.org/10.1523/JNEUROSCI.2045-11.2012 PMID: 22915103
67. Suzuki N, Mizuniwa C, Ishii K, Nakagawa Y, Tsuji K, Muneta T, et al. Teneurin-4, a transmembrane pro-
tein, is a novel regulator that suppresses chondrogenic differentiation. J Orthop Res. 2014; 32: 915–
922. https://doi.org/10.1002/jor.22616 PMID: 24648313
68. Zhang W, Zang Z, Song Y, Yang H, Yin Q. Co-expression network analysis of differentially expressed
genes associated with metastasis in prolactin pituitary tumors. Mol Med Rep. 2014; 10: 113–118.
https://doi.org/10.3892/mmr.2014.2152 PMID: 24736764
69. Noonan FC, Mutch DG, Ann Mallon M, Goodfellow PJ. Characterization of the homeodomain gene
EMX2: sequence conservation, expression analysis, and a search for mutations in endometrial cancers.
Genomics. 2001; 76: 37–44. https://doi.org/10.1006/geno.2001.6590 PMID: 11549315
70. Boeva V, Jouannet S, Daveau R, Combaret V, Pierre-Eugène C, Cazes A, et al. Breakpoint features of
genomic rearrangements in neuroblastoma with unbalanced translocations and chromothripsis. PLoS
ONE. 2013; 8: e72182. https://doi.org/10.1371/journal.pone.0072182 PMID: 23991058
71. Wang XZ, Jolicoeur EM, Conte N, Chaffanet M, Zhang Y, Mozziconacci MJ, et al. gamma-heregulin is
the product of a chromosomal translocation fusing the DOC4 and HGL/NRG1 genes in the MDA-MB-
175 breast cancer cell line. Oncogene. 1999; 18: 5718–5721. https://doi.org/10.1038/sj.onc.1202950
PMID: 10523851
72. Vinatzer U, Gollinger M, Mu¨llauer L, Raderer M, Chott A, Streubel B. Mucosa-associated lymphoid tis-
sue lymphoma: novel translocations including rearrangements of ODZ2, JMJD2C, and CNN3. Clin Can-
cer Res. 2008; 14: 6426–6431. https://doi.org/10.1158/1078-0432.CCR-08-0702 PMID: 18927281
73. Petrini I, Rajan A, Pham T, Voeller D, Davis S, Gao J, et al. Whole Genome and Transcriptome
Sequencing of a B3 Thymoma. PLoS ONE. 2013; 8: e60572. https://doi.org/10.1371/journal.pone.
0060572 PMID: 23577124
74. Vater I, Montesinos-Rongen M, Schlesner M, Haake A, Purschke F, Sprute R, et al. The mutational pat-
tern of primary lymphoma of the central nervous system determined by whole-exome sequencing. Leu-
kemia. 2015; 29: 677–685. https://doi.org/10.1038/leu.2014.264 PMID: 25189415
75. Hor H, Francescatto L, Bartesaghi L, Ortega-Cubero S, Kousi M, Lorenzo-Betancor O, et al. Missense
mutations in TENM4, a regulator of axon guidance and central myelination, cause essential tremor.
Hum Mol Genet. 2015; 24: 5677–5686. https://doi.org/10.1093/hmg/ddv281 PMID: 26188006
Teneurins and prognosis of ovarian cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0177244 May 4, 2017 24 / 24
